An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Celanese Announces Grant Award to Develop Long-Acting, Refillable Drug Delivery Solution
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Celanese Corporation (NYSE: CE) has received a grant from the Bill & Melinda Gates Foundation to develop a refillable contraceptive implant. This project aims to create a functional prototype within 18 months, focusing on enhancing access to contraceptive options for women in low- and middle-income countries. The development will leverage Celanese's VitalDose® drug delivery technology, which has a strong history in women's health. This initiative aligns with Celanese's mission to expand healthcare access globally.
Positive
Received a grant from the Bill & Melinda Gates Foundation for innovative contraceptive technology.
Project aims for prototype completion within 18 months, indicating a structured timeline.
Focus on addressing women's health issues in low- and middle-income countries enhances company reputation.
Utilization of VitalDose® technology showcases the company's capability in controlled drug release.
Negative
None.
Celanese to conduct research, prototype development and characterization of a refillable contraceptive technology with award from the Bill & Melinda Gates Foundation
DALLAS--(BUSINESS WIRE)--
Celanese Corporation (NYSE: CE), a global chemical and specialty materials company, today announced receipt of a grant from the Bill & Melinda Gates Foundation to produce and characterize a working prototype for a refillable contraceptive implant. The research and development will be conducted within the Celanese Pharmaceutical Development and Feasibility Lab and the project is expected to produce a functional prototype that meets all established project parameters within an 18-month timeframe.
The development of a refillable contraceptive implant has the potential to benefit women in low- and middle-income countries who presently either do not have access to modern contraceptive options or could benefit from the flexibility and control of the contraception this product design affords. Through this grant, Celanese will be providing critical research and development activities intended to facilitate and accelerate access to long-acting contraceptive options.
“We have a long history working in the area of women’s health and are honored by the trust placed in our team through this grant from the Gates Foundation,” said Laura Brand, vice president of the Celanese medical and pharmaceutical business. “The project concept is based on our VitalDose® drug delivery platform, a controlled release technology with decades of commercial use in the US and Europe. We are proud to be part of this opportunity to expand access to solutions for women’s health to many more women globally.”
Celanese offers cutting-edge medical and pharmaceutical material solutions and expert development support to pharmaceutical and medical device companies worldwide. With more than 40 years of experience supporting key applications and the demanding requirements of healthcare, Celanese continues to invest in this area, including by finding new ways to deliver a sustained dose of medication over time. The company’s expanding portfolio includes solutions and technologies for applications across drug delivery, medical devices, orthopedics, advanced surgical instruments and connected devices.
For more information on Celanese VitalDose technology, visit www.vitaldose.com.
About Celanese
Celanese Corporation is a global chemical leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Our businesses use the full breadth of Celanese's global chemistry, technology and commercial expertise to create value for our customers, employees, shareholders and the corporation. As we partner with our customers to solve their most critical business needs, we strive to make a positive impact on our communities and the world through The Celanese Foundation. Based in Dallas, Celanese employs approximately 8,500 employees worldwide and had 2021 net sales of $8.5 billion. For more information about Celanese Corporation and its product offerings, visit www.celanese.com.
What is the purpose of the grant received by Celanese from the Bill & Melinda Gates Foundation?
The grant is for developing a refillable contraceptive implant to enhance access to contraceptive options for women in low- and middle-income countries.
What is the timeline for the development of the refillable contraceptive prototype by Celanese?
Celanese aims to produce a functional prototype within an 18-month timeframe.
How does Celanese's VitalDose® technology relate to the new contraceptive implant project?
The project will utilize Celanese's VitalDose® technology, which is a controlled release drug delivery system with a successful history.
What are Celanese's goals in women's health through this project?
Celanese aims to provide critical research and development to facilitate access to long-acting contraceptive options for women.
What is the stock symbol for Celanese Corporation?
